LZL50 is an orally effective human caseinolytic protease P (hClpP) activator with an EC50 of 0.29 µM. LZL50 activates hClpP, a serine protease that mediates mitochondrial quality control by degrading damaged or misfolded mitochondrial proteins. LZL50 exhibits antitumor activity in a breast cancer xenograft mouse model. LZL50 can be used in research related to breast cancer[1].
Molekulargewicht:
555.61
Formel:
C31H33F4N3O2
Target-Kategorie:
Ser/Thr Protease
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
